Drug Profile
Emirodatamab - Amgen
Alternative Names: AMG-427; anti-FLT3 x anti-CD3 BiTE; Anti-FLT3/CD3-BiTE-antibody-AMG-427; FLT3 BiTE®; FLT3 HLE BITE®; FLT3/CD3-directed bispecific T-cell engager antibodyLatest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; BeiGene
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in China (IV, Infusion)
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in acute-myeloid-leukemia presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 28 Mar 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in Australia (IV, Infusion)